Your Position: Home > Technical Support > Basic Knowledge > Carcinogenic role of Epidermal growth factor receptor

Carcinogenic role of Epidermal growth factor receptor




Epidermal growth factor receptor(EGFR) is a trans-membrane glycoprotein.It has an extracellular epidermal growth factor binding domain and an intracellular tyrosine kinase domain. EGFR regulates signaling pathways to control cellular proliferation.EGFR binding to its ligand results in autophosphorylation by intrinsic tyrosine/kinase activity, triggering several signal transduction cascades. 

Constitutive or sustained activation of these sequences of downstream targets is thought to yield more aggressive tumor phenotypes. Mutations in EGFR have been discovered in association with some lung cancers. Lung adenocarcinomas with mutated EGFR have significant responses to tyrosine kinase inhibitors.Both EGFR mutation and gene amplification status may be important in determining which tumors will respond to tyrosine kinase inhibitors.

ELISA(enzyme-linked immunosorbent assay) is a method for detecting the concentration of some kind antigen or antibody,such as EGFR, using the characteristic of specific binding between antigen-antibody. The method is suitable for determination of cell culture supernatant, serum, plasma,tissue fluid, and urine samples. Meretciel provide high quality ELISA kits for R&D,can study the role of EGFR.

Hepatocellular carcinoma (HCC) is a frequent cancer like lung cancers.It has limited treatment options and poor prognosis. Tumorigenesis has been linked with macrophage-mediated chronic inflammation and diverse signalling pathways, including the EGFR pathway. The precise role of EGFR in HCC is unknown, and EGFR inhibitors have shown disappointing clinical results. But now, scientists discover that EGFR is expressed in liver macrophages in both human HCC and in a mouse HCC model. Mice lacking EGFR in macrophages show impaired hepatocarcinogenesis, whereas mice lacking EGFR in hepatocytes unexpectedly develop more HCC owing to increased hepatocyte damage and compensatory proliferation. 

Mechanistically, following interleukin-1 stimulation, EGFR is required in liver macrophages to transcriptionally induce interleukin-6, which triggers hepatocyte proliferation and HCC. Importantly, the presence of EGFR-positive liver macrophages in HCC patients is associated with poor survival. This study demonstrates a tumour-promoting mechanism for EGFR in non-tumour cells, which could lead to more effective precision medicine strategies.



Contact Us | About Us | Delivery | Feedback
Putus Macromolecular Sci. & Tech. Ltd All Rights Reserved. ©Copyright2012
Room7038, Hi-tech tower, Huaguang Road 18, East Lake New Technology Development Zone Tel: +86(0) 27 87610995 E-mail:
Skype Skype